- Home
- / Taysha Gene Therapies
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Taysha Gene Therapies financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.9
2024-10-29
Market Capitalization
$385.3 M
2024-10-29
Revenue
$9.8 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 11, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 2.5M | 15.5M | 8.3M | 9.8M | |
| General and administrative expense | 41.3M | 37.4M | 30.0M | 29.0M | 33.9M |
| Operating expense total | 173.3M | 164.9M | 87.9M | 95.0M | 120.3M |
| EBIT | (173.3M) | (162.4M) | (72.4M) | (91.5M) | (110.5M) |
| EBIT margin, % | -6492.7% | -468.8% | -1097.6% | -1130.6% | |
| Interest income | 172.0K | 249.0K | 3.6M | 6.9M | 9.2M |
| Interest expense | 1.4M | 3.8M | 5.0M | 5.3M | |
| Net Income | (174.5M) | (166.0M) | (111.6M) | (89.3M) | (109.0M) |
| EPS | (4.6) | (3.8) | (1.0) | (0.4) | (0.3) |